ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Transdermal delivery of risedronate via spanlastics for osteoporosis: formulation optimization, skin deposition, and pharmacokinetic assessment.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Baicalein-loaded nanocochleates for improving oral bioavailability: design, statistical optimization, and in vivo pharmacokinetic evaluation.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Risedronate is widely used for osteoporosis management, but its oral administration has limitations like poor bioavailability and gastrointestinal side effects. We developed and optimized a transdermal spanlastic formulation of risedronate to improve bioavailability. Risedronate-loaded spanlastics were formulated by ethanol injection and optimized through a Box-Behnken design. The effects of Span 60:Tween 40 ratio, stirring speed, and sonication time on vesicle size, polydispersity index (PDI), zeta potential, entrapment efficiency, and drug release were evaluated. The optimized spanlastics were incorporated into a Carbopol 934 gel for transdermal application and further studied for physicochemical parameters and pharmacokinetic evaluation in a rat model. The optimized vesicles exhibited a mean size of 191.80 ± 1.22 nm, PDI of 0.44 ± 0.06, zeta potential of - 27.2 ± 1.65 mV, entrapment efficiency of 90.49 ± 0.15%, and cumulative drug release of 95.16 ± 1.18% after 24 h. FTIR studies confirmed the absence of drug-excipient interactions, while TEM revealed spherical vesicles. Ex vivo studies demonstrated a twofold increase in skin permeation with spanlastics gel than plain drug gel. Skin irritation studies confirmed the biocompatibility of the optimized formulation. The pharmacokinetic parameters showed risedronate bioavailability improved by 1.84-fold versus plain drug and 3.90-fold versus a marketed formulation. The formulation was found to be stable for 6 months after the stability study. Risedronate-loaded spanlastics represent a promising transdermal delivery system that overcomes oral limitations by improving bioavailability and skin permeation. Still, further investigation of risedronate-loaded spanlastics gel in in vivo pharmacodynamics studies is necessary to confirm its potential in the long-term treatment of osteoporosis.
Indexed as
Identifiers
41313443What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.